文献速递白血病淋巴瘤

体内表达CD3/CD19双特异性T细胞衔接器与α-PD-L1-Fc对CD19⁺/PD-L1⁺白血病实现有效持久免疫治疗

In vivo expression of CD3/CD19 bispecific T-cell engager and α-PD-L1-Fc enables effective and durable immunotherapy for CD19+/PD-L1+ leukemia.
PubMed 文献 · Leukemia · 2025-12-23

约50%B-ALL患者对Blinatumomab(CD3/CD19双特异性T细胞衔接器)耐药,常伴肿瘤PD-L1高表达。研究开发经济、非病毒、单次肌注质粒基因递送系统,体内持续(≥4周)共表达CD3/CD19 BiTE和PD-L1抗体,整合T细胞介导细胞毒、免疫检查点阻断和抗体依赖细胞毒。CD19⁺/PD-L1⁺ Nalm-6异种移植完全缓解率80%,CD19抗原丢失免疫逃逸模型40%,疗效与CD3⁺、CD8⁺T细胞及CD3⁺CD56⁺NKT样细胞扩增、颗粒酶B/IFN-γ升高相关。

要点

  • 单次肌注质粒实现≥4周体内共表达CD3/CD19 BiTE与PD-L1抗体
  • CD19⁺/PD-L1⁺ Nalm-6异种移植完全缓解率80%,抗原丢失模型40%
  • 疗效与CD3⁺、CD8⁺T细胞及NKT样细胞扩增、颗粒酶B/IFN-γ升高相关

核心结论

  • 体内共表达CD3/CD19 BiTE与PD-L1抗体的非病毒质粒递送平台,可经济、持久、强效地整合T细胞衔接与PD-L1阻断,为B-ALL提供有转化前景的免疫治疗策略。

研究设计与样本

  • 研究开发非病毒、单次肌注质粒基因递送系统,在体内持续(≥4周)共表达CD3/CD19 BiTE和PD-L1抗体。
  • 在CD19⁺/PD-L1⁺ Nalm-6异种移植模型和CD19抗原丢失免疫逃逸模型中评价抗白血病疗效。
  • 在B-ALL患者来源CD3⁺T细胞中评价体内产生抗体的促增殖和肿瘤清除作用。

主要发现

  • CD19⁺/PD-L1⁺ Nalm-6异种移植中完全缓解(CR)率达80%,CD19抗原丢失免疫逃逸模型中CR率达40%。
  • 抗白血病疗效与CD3⁺、CD8⁺T细胞及CD3⁺CD56⁺NKT样细胞扩增、颗粒酶B/IFN-γ水平升高相关。
  • 体内产生的抗体促进B-ALL患者来源CD3⁺T细胞增殖和CD19⁺肿瘤细胞清除。

关键数值与推荐

  • 约50%B-ALL患者对Blinatumomab(CD3/CD19 BiTE)耐药,常伴肿瘤PD-L1高表达。
  • 该平台实现体内持续≥4周共表达CD3/CD19 BiTE和PD-L1抗体。
  • CD19⁺/PD-L1⁺ Nalm-6异种移植CR率80%,CD19抗原丢失免疫逃逸模型CR率40%。

临床怎么用

  • 该单次肌注质粒递送策略可能为B-ALL提供经济、持久、强效的体内免疫治疗选择。
  • 同时靶向CD3/CD19和PD-L1可能克服Blinatumomab耐药及PD-L1高表达导致的疗效受限。
  • 体内产生抗体可促进患者来源T细胞增殖和肿瘤清除,支持进一步转化研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Approximately 50% of B-ALL patients exhibit Blinatumomab (CD3/CD19 bispecific T-cell engager, BiTE) resistance, often with high tumor PD-L1 expression, limiting therapeutic efficacy. Combining Blinatumomab with PD-L1 blockade is promising but hindered by continuous infusion, short half-life, and high costs. We developed an economical, non-viral, single-dose intramuscular plasmid gene delivery for sustained (≥4 weeks) in vivo co-expression of CD3/CD19 BiTE and PD-L1 antibodies. This platform integrates T-cell-mediated cytotoxicity, immune checkpoint blockade, and antibody-dependent cytotoxicity. This strategy induced substantial leukemia cell regression, achieving an 80% complete remission (CR) rate in CD19⁺/PD-L1⁺ Nalm-6 xenografts and a 40% CR rate in the CD19 antigen-loss immune escape model. Anti-leukemic efficacy correlated with enhanced CD3⁺, CD8⁺ T-cell, CD3⁺CD56⁺ NKT-like cell expansion, and increased granzyme B/IFN-γ levels. Furthermore, in vivo-produced antibodies promoted B-ALL patient-derived CD3⁺ T-cell proliferation and CD19⁺ tumor cell clearance. This study presents a cost-effective, durable, and potent in vivo immunotherapy integrating T-cell engagement and PD-L1 blockade, offering a promising translational approach for B-ALL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Yang Y, Liu X, Wei J, et al. In vivo expression of CD3/CD19 bispecific T-cell engager and α-PD-L1-Fc enables effective and durable immunotherapy for CD19+/PD-L1+ leukemia. Leukemia. 2025. PMID: 41436638. doi:10.1038/s41375-025-02832-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。